Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-cash Items: 2017-2025

Historic Non-cash Items for Dianthus Therapeutics (DNTH) over the last 2 years, with Sep 2025 value amounting to $2.3 million.

  • Dianthus Therapeutics' Non-cash Items rose 86.17% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 86.17%. This contributed to the annual value of $24.9 million for FY2024, which is 681.74% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Non-cash Items stood at $2.3 million for Q3 2025, which was down 84.94% from $15.5 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Non-cash Items registered a high of $42.8 million during Q2 2024, and its lowest value of $776,110 during Q1 2024.
  • Its 3-year average for Non-cash Items is $8.5 million, with a median of $2.3 million in 2025.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 356.65% in 2023, then slumped by 83.88% in 2024.
  • Dianthus Therapeutics' Non-cash Items (Quarterly) stood at $1.7 million in 2022, then spiked by 356.65% to $3.2 million in 2023, then tumbled by 53.12% to $1.5 million in 2024, then surged by 86.17% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $15.5 million for Q2 2025, and $1.8 million during Q1 2025.